At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 120 target
Drug / intervention
Sarecycline Tablet +1 moredrug
Likely dose
Sarecycline Tablet 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy: A Phase II, Randomized, Multicenter, Double-blind, Single Dose, Placebo-controlled Parallel Trial
In Brief
A Phase 2 clinical trial evaluating Sarecycline Tablet and Placebo tablets of Sarecycline tablets for Ischemic Stroke, Acute. Targeting 120 participants across 1 site.
Detailed Summary
The aim of this study was to evaluate the efficacy and safety of Sarecycline versus placebo in the treatment of microcirculation dysfunction after reperfusion therapy in patients with large vessel occlusion stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke, Acute
CountriesChina
CollaboratorsNeurodawn Pharmaceutical Co., Ltd.
Timeline
Phase 2UnknownOverdue
202420252026
First PostedMay 2023
Enrollment StartMay 2023
Primary CompletionNov 2023
Study CompletionDec 2023
TodayJul 2026
First PostedMay 1, 2023
Enrollment StartMay 7, 2023
Primary CompletionNov 1, 2023
Study CompletionDec 1, 2023
TodayJul 1, 2026
Enrollment to primary: 6 monthsPosted 3.2 years ago
Interventions
Sarecycline Tabletdrug
Each tablet contained 100 mg of Sarecycline.
Placebo tablets of Sarecycline tabletsdrug
Each tablet contained 0 mg of Sarecycline.